Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

63.88 +1.02 (+1.62%)
Official Closing Price Updated: 7:00 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,018,717
Open 62.77
Bid (Size) 63.88 (100)
Ask (Size) 64.04 (400)
Prev. Close 62.86
Today's Range 62.30 - 63.93
52wk Range 42.52 - 68.64
Shares Outstanding 2,222,113,553
Dividend Yield 3.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple. 
Via The Motley Fool
News headline image
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗
Pharmaceutical company share prices may suffer, but probably not by as much as some might fear. 
Via The Motley Fool
Topics Bonds Economy

Performance

YTD
+19.5%
+19.5%
1 Month
-4.4%
-4.4%
3 Month
+9.1%
+9.1%
6 Month
+6.9%
+6.9%
1 Year
+44.7%
+44.7%

More News

Read More
News headline image
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question ↗
Via Chartmill
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup ↗
Via Chartmill
News headline image
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Healthcare Stocks That Fall Short
Via StockStory
News headline image
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? ↗
Via The Motley Fool
Topics Intellectual Property
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
News headline image
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
From Bristol Myers Squibb
Via Business Wire
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Via The Motley Fool
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
Via The Motley Fool
News headline image
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Sell BMY and 1 Stock to Buy Instead
Via StockStory
Topics Stocks

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 63.88
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 09/28/26 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 141.95B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 142B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.